Member area login

You don't have or don't remember the password!
Click Here

Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091

BC: Articoli scritti da L. Tripodi

Economical, legal and ethical considerations on reevaluation and retesting in molecular diagnostics

L. Pastore \| B. Lombardo \| M. Vitale \| L. Tripodi \| F. Amato \| M. Cosenza \| G. Giannini \|

Biochimica Clinica ; 46(3) 235-240 Opinioni - Opinions

Evaluation of the antiproliferative effect of Bifidobacterium longum BB-536 in solid tumor cell lines, co-cultured with murine splenocytes

L. Tripodi \| M. Passariello \| V. D'Argenio \| E. Leggiero \| M. Vitale \| R. Colicchio \| P. Salvatore \| V. Cerullo \| C. De Lorenzo \| L. Pastore \|
<p>Introduction: in the last decade, cancer immunotherapy has delivered impressive results in clinical settings. However, its efficacy has not been consistent probably because of several environmental and genetic factors influencing the outcome. Many studies have indicated that intestinal microbiota could affect the outcome of immune checkpoint inhibitors-based immunotherapy, both in animal models and patients. In particular, the Bifidobacterium genus seems to have a role as a positive regulator of in vivo antitumor immunity by promoting proinflammatory signals in innate immune cells. According to the considerable evidence that demonstrated its crucial role in the carcinogenesis and, overall, in the response to immunotherapy, we decided to use a commercial probiotic and grow its principal strain, the Bifidobacterium longum BB-536, in order to test its capability to affect antitumoral immune responses.<br />Methods: prior to in vivo studies, we carried out a feasibility evaluation study to test in vitro, antitumoral effects of the isolated probiotic strain. Tumor cell viability was used as parameter to determine Bifidobacterium longum BB-536 anti-proliferative ability before or after heat inactivation.<br />Results: interestingly, we found that B. longum inhibits cell growth, both in mouse melanoma B16-OVA and colorectal CT26 cells, showing a more pronounced effect on the latter ones.<br />Conclusion: this preliminary evaluation of live and heat-inactivated probiotic in tumor cell lines indicates a potential cell growth inhibitory effect of these bacterial strains and encourage further studies in mouse models.</p>
Biochimica Clinica ; 45(3) 242-247 Contributi Scientifici - Scientific Papers